Eyenovia Inc (EYEN)
0.7499
-0.07
(-8.65%)
USD |
NASDAQ |
May 17, 16:00
0.7499
0.00 (0.00%)
After-Hours: 16:18
Eyenovia Cash from Investing (Quarterly): -0.1452M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.1452M |
| September 30, 2023 | -1.703M |
| June 30, 2023 | -1.284M |
| March 31, 2023 | -0.8381M |
| December 31, 2022 | -0.3118M |
| September 30, 2022 | -0.1633M |
| June 30, 2022 | -0.192M |
| March 31, 2022 | -0.2077M |
| December 31, 2021 | -0.4535M |
| September 30, 2021 | -0.5173M |
| June 30, 2021 | -0.3034M |
| March 31, 2021 | -0.3443M |
| December 31, 2020 | -0.0592M |
| September 30, 2020 | -0.0698M |
| Date | Value |
|---|---|
| June 30, 2020 | -0.0383M |
| March 31, 2020 | -0.0939M |
| December 31, 2019 | -0.1232M |
| September 30, 2019 | -0.0435M |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | -0.0279M |
| September 30, 2018 | 0.00 |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | -0.007M |
| September 30, 2017 | 0.007M |
| June 30, 2017 | 0.002M |
| March 31, 2017 | -0.0122M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-1.703M
Minimum
Sep 2023
--
Maximum
Jun 2019
-0.3627M
Average
-0.192M
Median
Jun 2022
Cash from Investing (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | 1.068M |
| Alpine Immune Sciences Inc | -2.562M |
| Lantern Pharma Inc | -0.5562M |
| Oragenics Inc | -1.00M |
| MAIA Biotechnology Inc | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -6.322M |
| Cash from Financing (Quarterly) | 0.6143M |
| Free Cash Flow | -27.81M |
| Free Cash Flow Per Share (Quarterly) | -0.1335 |
| Free Cash Flow to Equity (Quarterly) | -6.652M |
| Free Cash Flow Yield | -90.39% |